Amyloidosis - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 152
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AEE243D42A6EN
Leaflet:

Download PDF Leaflet

Amyloidosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Amyloidosis - Pipeline Review, H2 2016’, provides an overview of the Amyloidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Amyloidosis
  • The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects
  • The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Amyloidosis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amyloidosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Amyloidosis Overview
Therapeutics Development
Pipeline Products for Amyloidosis - Overview
Pipeline Products for Amyloidosis - Comparative Analysis
Amyloidosis - Therapeutics under Development by Companies
Amyloidosis - Therapeutics under Investigation by Universities/Institutes
Amyloidosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Amyloidosis - Products under Development by Companies
Amyloidosis - Products under Investigation by Universities/Institutes
Amyloidosis - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arcturus Therapeutics, Inc.
BELLUS Health Inc.
Bsim2
Celgene Corporation
GlaxoSmithKline Plc
Ionis Pharmaceuticals, Inc.
Johnson & Johnson
Neurimmune Holding AG
NeuroPhage Pharmaceuticals, Inc.
Oncopeptides AB
Pfizer Inc.
Prothena Corporation Plc
Regeneron Pharmaceuticals, Inc.
SOM Innovation Biotech SL
Takeda Pharmaceutical Company Limited
Amyloidosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALN-ANG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALN-TTRsc02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daratumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDE-1307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2315698 + GSK-2398852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3039294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inotersen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUNAR-TTR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melflufen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEOD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
revusiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for AL Amyloidosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tafamidis meglumine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolcapone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amyloidosis - Dormant Projects
Amyloidosis - Product Development Milestones
Featured News & Press Releases
Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Jul 05, 2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis
Jul 01, 2016: Alnylam To Present New Results on Revusiran at the XV International Symposium on Amyloidosis
Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis
Jun 27, 2016: Alnylam to Present New Revusiran Results at the XV International Symposium on Amyloidosis
Jun 21, 2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
May 23, 2016: Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Amyloidosis, H2 2016
Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Amyloidosis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Amyloidosis - Pipeline by Amgen Inc., H2 2016
Amyloidosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016
Amyloidosis - Pipeline by BELLUS Health Inc., H2 2016
Amyloidosis - Pipeline by Bsim2, H2 2016
Amyloidosis - Pipeline by Celgene Corporation, H2 2016
Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2016
Amyloidosis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Amyloidosis - Pipeline by Johnson & Johnson, H2 2016
Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2016
Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2016
Amyloidosis - Pipeline by Oncopeptides AB, H2 2016
Amyloidosis - Pipeline by Pfizer Inc., H2 2016
Amyloidosis - Pipeline by Prothena Corporation Plc, H2 2016
Amyloidosis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
Amyloidosis - Pipeline by SOM Innovation Biotech SL, H2 2016
Amyloidosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Amyloidosis - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Amyloidosis, H2 2016
Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Amyloidosis - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 141 pages
Stroke - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 519 pages
DBV Technologies S.A. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 35 pages

Ask Your Question

Amyloidosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: